Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 54
- 试验地点
- 1
- 主要终点
- Prefrontal Glx Concentrations
研究概览
简要总结
The proposed 3-week, double-blind, crossover, proof of concept study aims to manipulate neurochemical dysfunctions characteristic of individuals with co-occurring BD and AUD (i.e., abnormally low prefrontal GABA and glutamate), using medications that have been shown to normalize cortical GABA (i.e., gabapentin) and glutamate (i.e., NAC) levels in past research, and to evaluate medication-related changes in response inhibition and alcohol cue-reactivity fMRI tasks as well as drinking and mood in individuals with AUD+BD.
详细描述
Bipolar disorder (BD) is the Axis I psychiatric condition most strongly associated with substance use disorder (SUD); diagnostic co-occurrence is particularly high between BD and alcohol use disorder (AUD). Individuals with co-occurring SUD and BD (SUD+BD) have substantially worse clinical outcomes than those with either BD or SUD alone. Nonetheless, little is known about optimal treatment for individuals with SUD+BD; response to lithium appears to be poor, and only one double-blind, randomized, placebo-controlled trial of valproate has demonstrated improved drinking outcomes in this population. Traditionally, treatment trials for SUD+BD have investigated medications that have been FDA approved to treat either BD or SUD in hopes that such medications would prove efficacious in individuals with SUD+BD. A different approach to selecting, and ideally developing, medications for SUD+BD treatment trials would be to target neurochemical dysfunctions characteristic of individuals with both BD and SUD. Recent research by the current investigator has demonstrated unique disturbances in prefrontal gamma-Aminobutyric acid (GABA) and glutamate concentrations in this population using proton magnetic resonance spectroscopy (1H-MRS), with individuals with co-occurring alcohol dependence (AD) and BD having significantly lower levels of GABA and glutamate relative to individuals with BD alone, AD alone, or healthy controls. Lower levels of prefrontal GABA and glutamate were in turn associated with elevated impulsivity and alcohol craving. The proposed 3-week, double-blind, crossover, proof of concept study will evaluate: a) whether medications that have been demonstrated to normalize cortical GABA (i.e., gabapentin) and glutamate (i.e., N-Acetylcysteine [NAC]) concentrations in individuals with epilepsy and cocaine dependence, respectively, may similarly act to normalize prefrontal GABA and glutamate levels in individuals with AUD+BD, and b) whether normalization of prefrontal GABA and glutamate levels will be associated with improvements in functional brain activity to tasks that assess core neurobehavioral deficits of AUD and BD (i.e., response inhibition, alcohol cue-reactivity), as well as drinking and mood symptoms. Positive results may support investigation of gabapentin and/or NAC as adjunctive treatments for AUD+BD in large-scale, randomized clinical trials. Most importantly, the proposed study may provide successful demonstration of a neuro-behavioral, multimodal neuroimaging platform for evaluating the potential promise of GABAergic and glutamatergic drugs for AUD and/or BD, as well as other conditions marked by GABAergic/glutamatergic dysfunction.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
Double-Blind
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Gabapentin, then N-Acetylcysteine, then Placebo Oral Capsule
Three, 1-week conditions.
Week 1 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Gabapentin: 5 day trial of gabapentin with titration to 1,200mg
Week 2 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
N-Acetylcysteine: 5 day trial of N-acetylcysteine with titration to 2,400mg
Week 3 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Placebo Oral Tablet: 5 day trial of matched placebo
干预措施: N-Acetylcysteine (Drug)
Gabapentin, then N-Acetylcysteine, then Placebo Oral Capsule
Three, 1-week conditions.
Week 1 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Gabapentin: 5 day trial of gabapentin with titration to 1,200mg
Week 2 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
N-Acetylcysteine: 5 day trial of N-acetylcysteine with titration to 2,400mg
Week 3 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Placebo Oral Tablet: 5 day trial of matched placebo
干预措施: Gabapentin (Drug)
Gabapentin, then N-Acetylcysteine, then Placebo Oral Capsule
Three, 1-week conditions.
Week 1 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Gabapentin: 5 day trial of gabapentin with titration to 1,200mg
Week 2 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
N-Acetylcysteine: 5 day trial of N-acetylcysteine with titration to 2,400mg
Week 3 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Placebo Oral Tablet: 5 day trial of matched placebo
干预措施: Placebo Oral Tablet (Drug)
N-Acetylcysteine, then Placebo Oral Capsule, then Gabapentin
3, 1 week conditions.
Week 1 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
N-Acetylcysteine: 5 day trial of N-acetylcysteine with titration to 2,400mg
Week 2 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Placebo Oral Tablet: 5 day trial of matched placebo
Week 3 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Gabapentin: 5 day trial of gabapentin with titration to 1,200mg
干预措施: N-Acetylcysteine (Drug)
N-Acetylcysteine, then Placebo Oral Capsule, then Gabapentin
3, 1 week conditions.
Week 1 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
N-Acetylcysteine: 5 day trial of N-acetylcysteine with titration to 2,400mg
Week 2 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Placebo Oral Tablet: 5 day trial of matched placebo
Week 3 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Gabapentin: 5 day trial of gabapentin with titration to 1,200mg
干预措施: Gabapentin (Drug)
N-Acetylcysteine, then Placebo Oral Capsule, then Gabapentin
3, 1 week conditions.
Week 1 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
N-Acetylcysteine: 5 day trial of N-acetylcysteine with titration to 2,400mg
Week 2 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Placebo Oral Tablet: 5 day trial of matched placebo
Week 3 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Gabapentin: 5 day trial of gabapentin with titration to 1,200mg
干预措施: Placebo Oral Tablet (Drug)
Placebo Oral Tablet, then Gabapentin, then N-Acetylcysteine
Three, 1-week conditions. Week 1 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Placebo Oral Tablet: 5 day trial of matched placebo
Week 2 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Gabapentin: 5 day trial of gabapentin with titration to 1,200mg
Week 3 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
N-Acetylcysteine: 5 day trial of N-acetylcysteine with titration to 2,400mg
干预措施: N-Acetylcysteine (Drug)
Placebo Oral Tablet, then Gabapentin, then N-Acetylcysteine
Three, 1-week conditions. Week 1 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Placebo Oral Tablet: 5 day trial of matched placebo
Week 2 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Gabapentin: 5 day trial of gabapentin with titration to 1,200mg
Week 3 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
N-Acetylcysteine: 5 day trial of N-acetylcysteine with titration to 2,400mg
干预措施: Gabapentin (Drug)
Placebo Oral Tablet, then Gabapentin, then N-Acetylcysteine
Three, 1-week conditions. Week 1 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Placebo Oral Tablet: 5 day trial of matched placebo
Week 2 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Gabapentin: 5 day trial of gabapentin with titration to 1,200mg
Week 3 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
N-Acetylcysteine: 5 day trial of N-acetylcysteine with titration to 2,400mg
干预措施: Placebo Oral Tablet (Drug)
Placebo Oral Capsule, then N-Acetylcysteine, then Gabapentin
Three, 1-week conditions.
Week 1 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Placebo Oral Tablet: 5 day trial of matched placebo
Week 2 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
N-Acetylcysteine: 5 day trial of N-acetylcysteine with titration to 2,400mg Week 3 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Gabapentin: 5 day trial of gabapentin with titration to 1,200mg
干预措施: N-Acetylcysteine (Drug)
Placebo Oral Capsule, then N-Acetylcysteine, then Gabapentin
Three, 1-week conditions.
Week 1 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Placebo Oral Tablet: 5 day trial of matched placebo
Week 2 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
N-Acetylcysteine: 5 day trial of N-acetylcysteine with titration to 2,400mg Week 3 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Gabapentin: 5 day trial of gabapentin with titration to 1,200mg
干预措施: Gabapentin (Drug)
Placebo Oral Capsule, then N-Acetylcysteine, then Gabapentin
Three, 1-week conditions.
Week 1 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Placebo Oral Tablet: 5 day trial of matched placebo
Week 2 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
N-Acetylcysteine: 5 day trial of N-acetylcysteine with titration to 2,400mg Week 3 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Gabapentin: 5 day trial of gabapentin with titration to 1,200mg
干预措施: Placebo Oral Tablet (Drug)
Gabapentin, then Placebo Oral Capsule, then N-Acetylcysteine
Three, 1-week conditions.
Week 1 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Gabapentin: 5 day trial of gabapentin with titration to 1,200mg
Week 2 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Placebo Oral Tablet: 5 day trial of matched placebo
Week 3 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
N-Acetylcysteine: 5 day trial of N-acetylcysteine with titration to 2,400mg
干预措施: N-Acetylcysteine (Drug)
Gabapentin, then Placebo Oral Capsule, then N-Acetylcysteine
Three, 1-week conditions.
Week 1 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Gabapentin: 5 day trial of gabapentin with titration to 1,200mg
Week 2 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Placebo Oral Tablet: 5 day trial of matched placebo
Week 3 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
N-Acetylcysteine: 5 day trial of N-acetylcysteine with titration to 2,400mg
干预措施: Gabapentin (Drug)
Gabapentin, then Placebo Oral Capsule, then N-Acetylcysteine
Three, 1-week conditions.
Week 1 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Gabapentin: 5 day trial of gabapentin with titration to 1,200mg
Week 2 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Placebo Oral Tablet: 5 day trial of matched placebo
Week 3 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
N-Acetylcysteine: 5 day trial of N-acetylcysteine with titration to 2,400mg
干预措施: Placebo Oral Tablet (Drug)
N-Acetylcysteine, then Gabapentin, then Placebo Oral Capsule
Three, 1-week conditions.
Week 1 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
N-Acetylcysteine: 5 day trial of N-acetylcysteine with titration to 2,400mg
Week 2 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Gabapentin: 5 day trial of gabapentin with titration to 1,200mg
Week 3 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Placebo Oral Tablet: 5 day trial of matched placebo
干预措施: N-Acetylcysteine (Drug)
N-Acetylcysteine, then Gabapentin, then Placebo Oral Capsule
Three, 1-week conditions.
Week 1 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
N-Acetylcysteine: 5 day trial of N-acetylcysteine with titration to 2,400mg
Week 2 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Gabapentin: 5 day trial of gabapentin with titration to 1,200mg
Week 3 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Placebo Oral Tablet: 5 day trial of matched placebo
干预措施: Gabapentin (Drug)
N-Acetylcysteine, then Gabapentin, then Placebo Oral Capsule
Three, 1-week conditions.
Week 1 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
N-Acetylcysteine: 5 day trial of N-acetylcysteine with titration to 2,400mg
Week 2 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Gabapentin: 5 day trial of gabapentin with titration to 1,200mg
Week 3 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
Placebo Oral Tablet: 5 day trial of matched placebo
干预措施: Placebo Oral Tablet (Drug)
结局指标
主要结局
Prefrontal Glx Concentrations
时间窗: Day 5 of each experimental condition
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy.
Prefrontal GABA+ Concentrations
时间窗: Day 5 of each experimental condition
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS).
次要结局
未报告次要终点
研究者
James J. Prisciandaro
Principal Investigator
Medical University of South Carolina